REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients...(E has satisfied unmet therapeutic needs ...)

Date:11/6/2007

E has satisfied unmet therapeutic needs and resulted in significant life-changing improvements in patients," said Thomas F. Schaible, PhD, Vice President, Medical Affairs, Centocor, Inc. "Almost a decade later, REMICADE continues to positively affect patients' lives and Centocor continues its commitment to developing novel and important therapies for diseases of the immune system."

"Around the world, the treatment of patients with inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease, has been transformed by the availability of REMICADE," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "Schering-Plough is committed to bringing the benefits of REMICADE, with its proven efficacy and rapid onset of action, to relieve the suffering of patients with these chronic inflammatory conditions."

Important firsts for REMICADE include:

-- In August 1998, REMICADE was approved on an accelerated basis for the

acute treatment of moderate-to-severe Crohn's disease in patients who

have had an inadequate response to conventional therapy and

fistulizing disease. This approval made REMICADE the first TNF-alpha

inhibitor available in the U.S.

-- In August 1999, REMICADE became the first TNF-alpha inhibitor approved

in the European Union (EU) for the short-term treatment of severe,

active Crohn's disease and fistulizing, active Crohn's disease in

patients who have not responded to conventional therapy.

-- In December 2001, REMICADE became the first TNF-alpha inhibitor

approved in Japan for the treatment of moderate-to-severe Crohn's

disease.

-- In February 2002, REMICADE became the first TNF-alpha inhibitor

indicated in the U.S. to improve physical function in patients with

moderate to severe RA who have had an i
'/>"/>

SOURCE Centocor, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
7. Genmab Announces 2007 First Half Year Results
8. Pharsight Achieves First License Sale for Public-Source Database
9. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. China Medical Technologies Reports First Quarter Financial Results